Interleukin-1 alpha-induced tumour pathophysiologies can be exploited with bioreductive alkylating agents.
Braunschweiger
P G
PG
Department of Radiation Oncology, Sylvester Cancer Center, University of Miami, FL 33101.
Jones
S A
SA
Johnson
C S
CS
Furmanski
P
P
D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002470:Cell Survival / Q000187:drug effects; D007275:Injections, Intravenous; D007375:Interleukin-1 / Q000627:therapeutic use*; D051379:Mice; D008809:Mice, Inbred C3H; D008920:Misonidazole / Q000008:administration & dosage / Q000031:analogs & derivatives; D016685:Mitomycin; D008937:Mitomycins / Q000008:administration & dosage; D009368:Neoplasm Transplantation; D009374:Neoplasms, Experimental / Q000188:drug therapy*; D011160:Porfiromycin / Q000008:administration & dosage; D000077704:Tirapazamine; D014227:Triazines / Q000008:administration & dosage
D007375:Interleukin-1; D008937:Mitomycins; D014227:Triazines; D000077704:Tirapazamine; D016685:Mitomycin; C041712:1-(2-nitro-1-imidazolyl)-3-aziridino-2-propanol; D008920:Misonidazole; D011160:Porfiromycin